1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Defence Therapeutics Inc.
  6. News
  7. Summary
    DTC   CA24463V1013

DEFENCE THERAPEUTICS INC.

(DTC)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Defence Therapeutics Inc. Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of CRISPR/Cas9 Protein to Target Cells

12/13/2021 | 08:00am EDT

Defence Therapeutics Inc. announced that its AccumTM platform can potently enhance Cas9 delivery in target cells, which would have a significant positive impact on the CRISPR industry. The CRISPR technology offers the potential to transform medicine, enabling both the treatment or prevention of many illnesses by deleting or inserting genes in a targeted manner. This technology is central to the biotech industry as it can be used to treat multiple illnesses such as cancer, viral diseases (HIV and Hepatitis B) as well as several genetic disorders. The essence of this technology is simple and requires two important tools: 1) a piece of genetic material to guide the editing process, and 2) the co-delivery of a Cas protein to cut/edit the DNA. Of all the Cas protein currently identified, Cas9 is the most widely used by scientists as it can easily find and bind to almost any desired target sequence, simply by giving a piece of RNA to guide it in its search. Delivery of the Cas9 protein instead of a DNA-encoding sequence gives the advantage of decreasing off-target activity of Cas9. The current and existing protein delivery tools available are inefficient at delivering proteins inside the nucleus of target cells. More specifically, any delivered protein ends-up being entrapped and degraded within small endosome-lysosome vesicles. Consequently, the pool of cytosolic Cas9 is low in magnitude making it difficult to reach the nucleus for efficient DNA editing activity. As such, multiple deliveries have to be attempted to reach enough nuclear Cas9 material. The AccumTM platform is designed to accumulate a given molecule in target cells. The Defence team has tested AccumTM's ability to improve Cas9 delivery to cells. The obtained results, with only a single AccumTM dose and without any added use of a complex lipid formulation, are astonishing. The accumulation of AccumTM-linked Cas9 inside the nucleus of the cells was at least 9-fold higher of the free Cas9 when added to mammalian cells in vitro. With such amazing data in hand, Defence will actively be looking to partner with major players in the field in order to move forward on CRISPR-based treatments designed for specific indications.


© S&P Capital IQ 2021
All news about DEFENCE THERAPEUTICS INC.
05/18Defence?s novel accuvac-pte7 vaccine shows complete protection from cervical cancer
EQ
05/18Defence Therapeutics Inc.'s Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from C..
CI
04/07Defence therapeutics announces issuance of a u.s. patent covering its pioneering vaccin..
EQ
03/22DEFENCE THERAPEUTICS : An anti-cancer solutions platform company advancing its versatile a..
EQ
03/22Defence Therapeutics Inc. Provides an Overview of Its Current Research and Development ..
CI
02/28Defence Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
02/28DEFENCE THERAPEUTICS INC. : Defence releases peer-reviewed publication of its preclinical ..
EQ
02/28Defence Therapeutics Inc. Releases Peer-Reviewed Publication of Its Preclinical Data on..
CI
02/16DEFENCE THERAPEUTICS INC. : Defence retains cato sms to advise on its phase i clinical tri..
EQ
01/26DEFENCE THERAPEUTICS INC. : Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) acti..
EQ
More news
Financials
Sales 2021 - - -
Net income 2021 -2,86 M -2,23 M -2,23 M
Net cash 2021 5,45 M 4,25 M 4,25 M
P/E ratio 2021 -65,6x
Yield 2021 -
Capitalization 117 M 91,0 M 91,0 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float 93,9%
Chart DEFENCE THERAPEUTICS INC.
Duration : Period :
Defence Therapeutics Inc. Technical Analysis Chart | DTC | CA24463V1013 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,20 CAD
Average target price 11,02 CAD
Spread / Average Target 244%
Managers and Directors
Sébastien Plouffe President, Chief Executive Officer & Director
P. Joseph Meagher Chief Financial Officer & Director
Raimar Löbenberg Chairman
Simon Beaudoin Chief Technology & Science Officer
Moutih Rafei Director & VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
DEFENCE THERAPEUTICS INC.-40.74%91
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418